Please Wait.....
Report
Oncolytic Virus Cancer Therapy - Market Insight, Epidemiology and Market Forecast - 2032
Market Report I 2022-09-01 I 239 Pages I DelveInsight
DelveInsight's " Oncolytic Virus Therapies (OVTs)- Market Insight, Epidemiology and Market Forecast Forecast-2032" report delivers an in-depth understanding of the Oncolytic Virus Therapies (OVTs), historical and forecasted epidemiology as well as the Oncolytic Virus Therapies (OVTs) trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Oncolytic Virus Therapies (OVTs) market report provides emerging drugs, Oncolytic Virus Therapies (OVTs) market share of the individual cancer types, current and forecasted Oncolytic Virus Therapies (OVTs) market size from 2019 to 2032 segmented by seven major markets. The Report also covers current OVTs unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Oncolytic Virus Therapies (OVTs) Understanding and Treatment Algorithm
The DelveInsight's Oncolytic Virus Therapies (OVTs) epidemiology report gives a thorough understanding of OVTs by including details such as overview of OVTs, advantages, disadvantages and available therapies. Comprehensive epidemiology insight of the tumors targeted by OVTs. Oncolytic viruses (OVs), considered an effective anticancer strategy in recent years, are a special type of virus that are naturally or genetically engineered and can replicate preferentially in tumor cells and inhibit tumor growth. OVT is a treatment using a virus that can replicate itself to kill cancer cells. Many species of viruses exist, but not all can be designed to be oncolytic viruses (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity to be transformed to express tumor-killing factors through genetic engineering methods.
OVs have proven to be a powerful anticancer molecule, being able to be used for cancer diagnosis as well as treatment. Their multifunctional characteristics indicate good application prospects as cancer therapeutics, especially in combination with other therapies, such as radiotherapy, chemotherapy, and immunotherapy. Currently, only two oncolytic virus therapies are approved, namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen) approved in the US and Europe in 2015, and DELYTACT (teserpaturev/G47?; Daiichi Sankyo) approved in Japan in 2021.
Oncolytic Virus Therapies (OVTs) Epidemiology
The epidemiology section provides the insights about historical and current indication wise eligible patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Oncolytic Virus Therapies (OVTs) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In 2021, the total indication wise target patient pool cases across 7MM were about 632 K which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted intratumoral cancer therapies epidemiology [segmented as Total Incident cases of selected cancer types (Melanoma, Nonmelanoma skin cancer, Pancreatic Cancer, Renal cell carcinoma, Prostate Cancer, Brain Cancer, Bladder cancer, and Ovarian cancer), Target patient Pool of intratumoral therapies by Cancer Types and Treated cases by Cancer Types] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Oncolytic Virus Therapies (OVTs) Epidemiology
The epidemiology segment also provides the OVTs epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Oncolytic Virus Therapies (OVTs) Drug Chapters
The drug chapter segment of the Oncolytic Virus Therapies (OVTs) report encloses the detailed analysis of OVTs marketed drugs and late stage (Phase III and Phase II) pipeline drugs. It also helps to understand the OVTs clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Emerging Drugs
The report provides the details of the emerging OVTs under the late and mid-stage of development for selected indications treatment.
Oncolytic Virus Therapies (OVTs) Market Outlook
The Oncolytic Virus Therapies (OVTs) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted OVTs market trends by analyzing the impact of current therapies on the market, unmet needs, and demand of better technology.
This segment gives a thorough detail of OVTs market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the OVTs market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
The OVTs market size in the 7MM is expected to change during the study period 2019-2032. The OVTs therapeutic market in the seven major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of OVTs was approximately USD 122 million which is expected to rise during the study period (2019-2032).
The United States Market Outlook
The total market size of OVTs in the United States accounted for USD 84 million in 2021 which is expected to rise during the study period (2019-2032).
EU-5 Countries: Market Outlook
In EU5, the total market size of OVTs was about USD 38 million in 2021, which is expected to rise during the study period (2019-2032).
Japan Market Outlook
In Japan, the total market size of OVTs was USD 0.01 million in 2021, which is expected to rise during the study period (2019-2032).
Oncolytic Virus Therapies (OVTs) Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the OVTs market or expected to get launched in the market during the study period 2019-2032. The analysis covers Oncolytic Virus Therapies (OVTs) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Oncolytic Virus Therapies (OVTs) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses key players involved in developing OVTs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing patent details, and other information for emerging OVTs.
Reimbursement Scenario in Oncolytic Virus Therapies (OVTs)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the OVTs domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or OVTs market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitively and Market Intelligence analysis of the OVTs Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers a detailed overview of the development of OVTs across the several selected indications, explaining its various classes, benefits, and challenges for future
- Comprehensive insight has been provided into the OVTs epidemiology and treatment in the 7MM.
- Additionally, an all-inclusive account of both the current and emerging OVTs is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of OVTs market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global OVTs market.
Report Highlights
- In the coming years, OVTs market is set to change due to improved patient outcomes, treatment of cold tumors, rich emerging pipeline and convenient production and administration; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence OVTs R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for OVTs. Launch of emerging therapies, will significantly impact the OVTs market.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Oncolytic Virus Therapies (OVTs) Report Insights
- Patient Population
- Therapeutic Approaches
- Oncolytic Virus Therapies (OVTs) Pipeline Analysis
- Oncolytic Virus Therapies (OVTs) Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Oncolytic Virus Therapies (OVTs) Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Oncolytic Virus Therapies (OVTs) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Oncolytic Virus Therapies (OVTs) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
Key Questions
Market Insights:
- What was the OVTs Market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the OVTs total market size as well as market size by therapies across the 7MM during the study period (2019-2032)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest OVTs market size during the study period (2019-2032)?
- At what CAGR, the OVTs market is expected to grow in the 7MM during the study period (2019-2032)?
- What would be the OVTs market outlook across the 7MM during the study period (2019-2032)?
- What would be the OVTs market growth till 2032 and what will be the resultant market size in the year 2032?
- OVTs patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
Epidemiology Insights:
- What is the challenges and unmet needs of the OVTs?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical OVTs patient pool in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
- What would be the forecasted patient pool of OVTs in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to OVTs?
- Out of all the 7MM countries, which country would have the highest incident population of Oncolytic Virus Therapies (OVTs) during the study period (2019-2032)?
- At what CAGR the population is expected to grow by 7MM during the study period (2019-2032)?
- What are the various recent and upcoming events which are expected to improve the uptake of Oncolytic Virus Therapies (OVTs)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the marketed OVTs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing OVTs for the treatment of selected cancers?
- How many OVTs are in-development by each company for selected cancer treatment?
- How many are emerging OVTs in mid-stage, and late stage of development for selected cancers treatment?
- What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the OVTs?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for OVTs and its status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging OVTs?
- What are the global historical and forecasted markets of OVTs?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the OVTs market
- To understand the future market competition in the OVTs market and Insightful review of the key unmet needs
- Organize sales and marketing efforts by identifying the best opportunities for OVTs in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the OVTs market
- To understand the future market competition in the OVTs market
1. Key Insights
2. Report Introduction
3. OVTs Market Overview at a Glance
3.1. Market Share (%) Distribution of OVTs in 2019: By Country
3.2. Market Share (%) Distribution of OVTs in 2032: By Country
3.3. Market Share (%) Distribution of OVTs in 2025: By Indication
3.4. Market Share (%) Distribution of OVTs in 2032: By Indication
4. Key Highlights from Report
5. Executive Summary of OVTs
5.1. Key Events
6. Epidemiology and Market Forecast Flow
7. Background and Overview
7.1. Introduction
7.2. Different types of OVs
7.3. Applications of OVs
7.3.1. Cancer diagnosis
7.3.2. Cancer treatment
7.4. Multiple Mechanisms of Action of OVs for Cancer Therapy
7.4.1. Mechanism of tumor selectivity
7.4.2. Mechanisms of action of viruses destroying cancer cells
7.5. Routes of Administration
7.5.1. Direct intratumoral delivery
7.5.2. IV delivery
7.5.3. Other routes of delivery
7.5.4. Comparing different administration routes
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale
8.3. Epidemiology Scenario in the 7MM
8.3.1. Total Incident cases of selected cancer types across the 7MM
8.3.2. Target Patient Pool of OVTs by Cancer Types across the 7MM
8.3.3. Treated cases by Cancer types across the 7MM
8.4. Epidemiology Scenario in the US
8.4.1. Total Incident cases of selected cancer types across the US
8.4.2. Target Patient Pool of OVTs by Cancer Types across the US
8.4.3. Treated cases by Cancer Types across the US
8.6. Epidemiology Scenario in EU5
8.6.1. Total Incident cases of selected cancer types across EU5
8.6.2. Target Patient Pool of OVTs by Cancer Types across EU5
8.6.3. Treated cases by Cancer Types across EU5
8.7. Epidemiology Scenario in Japan
8.7.1. Total Incident cases of selected cancer types across Japan
8.7.2. Indication wise target patient pool across Japan
8.7.3. Treated cases by Cancer Types across Japan
9. Key Endpoints in OVTs
10. Marketed therapies
10.1. Key Cross of Marketed Therapies
10.2. IMLYGIC (talimogene laherparepvec): Amgen
10.2.1. Product description
10.2.2. Regulatory milestones
10.2.3. Other developmental activities
10.2.4. Pivotal clinical trial
10.2.5. Ongoing pipeline activity
10.3. DELYTACT (G47?): Daiichio Sankyo
10.3.1. Product description
10.3.2. Regulatory milestones
10.3.3. Other developmental activities
10.3.4. Pivotal clinical trials
11. Emerging Therapies
11.1. Key Cross Competition
11.2. ONCOS-102: Targovax
11.2.1. Product description
11.2.2. Other developmental activities
11.2.3. Clinical development
11.2.4. Safety and efficacy
11.3. RP1 (Vusolimogene Oderparepvec): Replimune
11.3.1. Product description
11.3.2. Other developmental activities
11.3.3. Clinical development
11.3.4. Safety and efficacy
11.4. GL-ONC1: Genelux Corporation
11.4.1. Product description
11.4.2. Other developmental activities
11.4.3. Clinical development
11.4.4. Safety and efficacy
11.5. CAN-2409: Candel Therapeutics
11.5.1. Product description
11.5.2. Other Developmental Activities
11.5.3. Clinical development
11.5.4. Safety and efficacy
11.6. DNX-2401 (Tasadenoturev): DNAtrix
11.6.1. Product description
11.6.2. Other developmental activities
11.6.3. Clinical development
11.6.4. Safety and efficacy
11.7. PEXA-VEC (Pexastimogene Devacirepvec; JX-594): SillaJen
11.7.1. Product description
11.7.2. Other developmental activities
11.7.3. Clinical development
11.7.4. Safety and efficacy
11.8. G207: Treovir
11.8.1. Product description
11.8.2. Other developmental activities
11.8.3. Clinical development
11.8.4. Safety and efficacy
11.9. LOAd703: Lokon Pharma AB
11.9.1. Product description
11.9.2. Other developmental activities
11.9.3. Clinical development
11.9.4. Safety and efficacy
11.10. Lerapolturev (Formerly Known as PVSRIPO): Istari Oncology
11.10.1. Product description
11.10.2. Other developmental activities
11.10.3. Clinical development
11.10.4. Safety and efficacy
11.11. CG0070: CG Oncology
11.11.1. Product description
11.11.2. Other developmental activities
11.11.3. Clinical development
11.11.4. Safety and efficacy
12. Attribute Analysis
13. Oncolytic virus therapies: 7 Major Market Analysis
13.1. Key Findings
13.2. Market Outlook
13.3. Market Size of OVTs in the 7MM
13.3.1. Total Market Size of OVTs
13.3.2. Total Market Size of OVTs by Indications in the 7MM
13.3.3. Market Size of OVTs by Therapies
13.4. Market Size of OVTs in the US
13.4.1. Total Market Size of OVTs
13.4.2. Total Market Size of OVTs by Indications
13.4.3. Market Size of OVTs by Therapies in the US
13.5. Market Size of OVTs in EU5
13.5.1. Total Market Size of OVTs
13.5.2. Total Market Size of OVTs by Indications
13.5.3. Market Size of OVTs by Therapies in EU5
13.6. Market Size of OVTs in Japan
13.6.1. Total Market Size of OVTs
13.6.2. Total Market Size of OVTs by Indications
13.6.3. Market Size of OVTs by Therapies in Japan
14. Market Access and Reimbursement
14.1. NICE UK
14.2. IQWiG and GBA Assessment
14.3. Japan
14.4. Patient assistance programs
15. KOL Views
16. SWOT Analysis
17. Unmet Needs
18. Appendix
18.1. Acronyms and Abbreviations
18.2. Bibliography
18.3. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Table 1: Summary of OVTs
Table 2: Use of OVs for Cancer Diagnosis
Table 3: Administration Routes of OVs in Multiple Tumors
Table 4: Comparison Between Different Administration Methods
Table 5: Incident cases (2020) and Year-over-year (YOY) cancer growth rates
Table 6: Total incident cases of selected cancer types across the 7MM (in Thousands) (2019-2032)
Table 7: Target patient Pool of OVTs by Cancer Types across the 7MM (in Thousands) (2019-2032)
Table 8: Treated cases by Cancer Types across the 7MM (in Thousands) (2019-2032)
Table 9: Total Incident cases of selected cancer types across the US (in Thousands) (2019-2032)
Table 10: Target patient Pool of OVTs by Cancer Types across the US (in Thousands) (2019-2032)
Table 11: Treated cases by Cancer Types across the US (in Thousands) (2019-2032)
Table 12: Total Incident cases of selected cancer types across EU5 (in Thousands) (2019-2032)
Table 13: Total Target patient Pool of OVTs by Cancer Types across EU5 (in Thousands) (2019-2032)
Table 14: Treated cases by Cancer Types across EU5 (in Thousands) (2019-2032)
Table 15: Total Incident cases of selected cancer types in Japan (in Thousands) (2019-2032)
Table 16: Target patient Pool of OVTs by Cancer Types in Japan (in Thousands) (2019-2032)
Table 17: Treated cases by Cancer Types in Japan (in Thousands) (2019-2032)
Table 18: Summary of Results for the ITT Population From IMLYGIC Study 005/05
Table 19: IMLYGIC , Clinical Trial Description, 2022
Table 20: Results on Tumor Reduction Effect and Safety
Table 21: Comparison of emerging drugs under development
Table 22: ONCOS-102; Clinical Trial Description, 2022
Table 23: RP1; Clinical Trial Description, 2022
Table 24: Olvi-Vec; Clinical Trial Description, 2022
Table 25: DNX-2401; Clinical Trial Description, 2022
Table 26: Pexa-Vec (pexastimogene devacirepvec; JX-594), Clinical Trial Description, 2022
Table 27: G207; Clinical Trial Description, 2022
Table 28: LOAd703, Clinical Trial Description, 2022
Table 29: PVSRIPO; Clinical Trial Description, 2022
Table 30: 7MM Market Size of OVTs in USD Million (2019-2032)
Table 31: 7MM Market Size of OVTs By Indications in USD Million (2019-2032)
Table 32: 7MM Market Size of OVTs in USD Million (2019-2032)
Table 33: US Market Size of OVTs in USD Million (2019-2032)
Table 34: US Market Size of OVTs By Indications in USD Million (2019-2032)
Table 35: US Market Size of OVTs in USD Million (2019-2032)
Table 36: EU5 Market Size of OVTs in USD Million (2019-2032)
Table 37: EU5 Market Size of OVTs By Indications in USD Million (2019-2032)
Table 38: EU-5 Market Size of OVTs by Therapies in USD Million (2018-2032)
Table 39: Japan Market Size of OVTs in USD Million (2019-2032)
Table 40: Japan Market Size of OVTs By Indications in USD Million (2019-2032)
Table 41: Japan Market Size of OVTs in USD Million (2019-2032)
Table 42: NICE Assessment for OVT
Figure 1: Milestone of OVTs Development
Figure 2: OVs as Cancer Therapy
Figure 3: The combination of OVTs with Other Therapeutic Approaches
Figure 4: The Multiple Modes of Action of an OV
Figure 5: Virus Targeting Tumor Cells in Various Ways
Figure 6: Mechanism of Anticancer Activity of OVs
Figure 7: Global Heat Map of all cancers in 2020, both sexes, all ages
Figure 8: Total incident cases of selected cancer types across the 7MM (2019-2032)
Figure 9: Target patient Pool of OVTs by Cancer Types across the 7MM (2019-2032)
Figure 10: Treated cases by Cancer Types across the 7MM (2019-2032)
Figure 11: Total Incident cases of selected cancer types across the US (2019-2032)
Figure 12: Target patient Pool of OVTs by Cancer Types across the US (2019-2032)
Figure 13: Treated cases by Cancer Types in the US (2019-2032)
Figure 14: Total Incident cases of selected cancer types in EU5 (2019-2032)
Figure 15: Target patient Pool of OVTs by Cancer Types across EU5 (2019-2032)
Figure 16: Treated cases by Cancer Types across EU5 (2019-2032)
Figure 17: Total Incident cases of selected cancer types in Japan (2019-2032)
Figure 18: Indication wise target patient pool across Japan (2019-2032)
Figure 19: Treated cases by Cancer Types across Japan (2019-2032)
Figure 20: Structure of DNX-2401 (tasadenoturev)
Figure 21: Mode of Action of Pexa-Vec
Figure 22: Market Size of OVTs in the 7MM, USD Million (2019-2032)
Figure 23: Market Size of OVTs By Indications in the 7MM, USD Million (2019-2032)
Figure 24: 7MM Market Size of Oncolytic Virus Therapies in USD Million (2019-2032)
Figure 25: Market Size of OVTs in the US, USD Million (2019-2032)
Figure 26: Market Size of OVTs By Indications in the US, USD Million (2019-2032)
Figure 27: US Market Size of OVTs in USD Million (2019-2032)
Figure 28: Market Size of OVTs in EU5, USD Million (2019-2032)
Figure 29: Market Size of OVTs By Indications in the EU5, USD Million (2019-2032)
Figure 30: EU5 Therapywise market size of OVTs in USD Million (2019-2032)
Figure 31: Market Size of OVTs in Japan, USD Million (2019-2032)
Figure 32: Market Size of OVTs By Indications in Japan, USD Million (2019-2032)
Figure 33: Japan Market Size of OVTs in USD Million (2019-2032)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security